Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-30476622

RESUMEN

In 2006 the National Toxicology Program (NTP) of the FDA shifted to the preferred use of Wistar-Han rats from the more commonly used Sprague-Dawley (SD) strain - and industry followed. While European laboratories preferred the Wistar-Han line, there was a paucity of relevant historical control data in many US research institutions for the new "industry standard" rat strain. In 2010 the NTP reversed its decision and shifted back to SD rats because of reproductive issues with the Wistar strain. For post hoc comparative analyses, we report minimal practical differences in Functional Observational Battery (FOB) data from a large sample of male and female Wistar-Han and SD rats. In summarizing data from the preclinical safety evaluations of the CNS effects of new drugs using the FOB, it is crucial to understand the value of not only how the functional expression of drug effects in the rat are predictive of the human response, but also how and why they differ. What we can predict from the behavioral and physiological response of the designated test system to drug administration is the foundation of "generalizability" to the human's response. Here, we conclude that the use of either SD or WH rat strains in standard CNS safety studies provide equivalent supportive data for CNS safety assessment required for IND approval under the harmonized guidelines.


Asunto(s)
Sistema Nervioso Central/efectos de los fármacos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/fisiopatología , Modelos Animales , Ratas/fisiología , Pruebas de Toxicidad/métodos , Animales , Conducta Animal/efectos de los fármacos , Sistema Nervioso Central/fisiopatología , Femenino , Guías como Asunto , Masculino , Ratas Sprague-Dawley , Ratas Wistar , Especificidad de la Especie , Pruebas de Toxicidad/normas , Estados Unidos , United States Food and Drug Administration
3.
J Pharmacol Toxicol Methods ; 82: 90-108, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27534836

RESUMEN

The International Conference on Harmonisation's (ICH) Tripartite Guideline on Safety Pharmacology Studies for Human Pharmaceuticals has adopted the requirement that each new test substance must be tested for effects on the central nervous system prior to "first dose in man". This assessment is required to measure, at a minimum, the effects of the substance on general motor activity, behavioral changes, coordination, sensory/motor reflex responses, and body temperatures. To achieve this goal, ICH S7A recommends a neurobehavioral assessment (usually a functional observational battery (FOB) or modified Irwin test), which is generally undertaken in the rat. There seems to be a growing lack of consensus on the value of the FOB to determine CNS safety. This review highlights the importance of the time, effort and cost of training technicians to familiarize with their instrument of measure, so that each observer is better able to identify and document very subtle changes in behavior that will serve to increase the reliability and validity of these assays with respect to CNS safety assessments.


Asunto(s)
Conducta Animal/efectos de los fármacos , Sistema Nervioso Central/efectos de los fármacos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Ratas , Pruebas de Toxicidad/métodos , Animales , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/psicología , Especificidad de la Especie , Pruebas de Toxicidad/normas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...